Literature DB >> 7879319

Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.

J Zorzos1, D V Skarlos, P Pozatzidou, A Zizi, A Bakiras, S Koritsiadis, D Pectasidis, P Koutsioumba, A A Epenetos, M Likourinas.   

Abstract

The monoclonal antibody AUA1, labelled with 2 or 3 mCi iodine-131, was administered intravesically to 11 patients with known or suspected bladder carcinoma and was kept in the bladder for 1 h. All patients underwent immunoscintigraphy of the bladder at 2 h and three patients also at 20 h after instillation. Conventional histological and immunohistochemical examinations were performed on tissue samples from tumour and normal areas taken during cystoscopy, carried out 24-h after the instillation. Transitional cell carcinoma of the bladder was present in nine patients whereas dysplastic and normal urothelium was found in the remaining two patients, respectively. Six out of nine tumours were successfully imaged at the 2-h scan. Normal urothelium showed no uptake while dysplastic urothelium was positive on imaging. Successful detection was correlated with size and grade of tumour in almost all cases. Tumors with a diameter of 1 cm or less were not detected. Four out of five grade II tumours and two out of three grade III tumours were detected with this method. The method is a promising one although further studies using more suitable isotopes and/or monoclonal antibodies are required to increase its sensitivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7879319     DOI: 10.1007/bf00297203

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  20 in total

1.  Further characterization, isolation and identification of the epithelial cell-surface antigen defined by monoclonal antibody AUA1.

Authors:  H Durbin; N Rodrigues; W F Bodmer
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

2.  Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI.

Authors:  N K Spurr; H Durbin; D Sheer; M Parkar; L Bobrow; W F Bodmer
Journal:  Int J Cancer       Date:  1986-11-15       Impact factor: 7.396

3.  Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.

Authors:  E Anagnostaki; D Skarlos; N Tamvakis; P Psaropoulou; E Blana; A Bamias; S Legaki; G Aravantinos; C Deliveliotis; K Dimopoulos
Journal:  Br J Cancer Suppl       Date:  1990-07

4.  Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder.

Authors:  E Huland; H Huland; T Meier; O Baricordi; Y Fradet; H B Grossman; G M Hodges; E M Messing; B J Schmitz-Draeger
Journal:  J Urol       Date:  1991-12       Impact factor: 7.450

5.  Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix.

Authors:  A A Epenetos; D Snook; G Hooker; R Begent; H Durbin; R T Oliver; W F Bodmer; J P Lavender
Journal:  Lancet       Date:  1985-08-17       Impact factor: 79.321

6.  Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas.

Authors:  A Bamias; M J Bowles; T Krausz; G Williams; A A Epenetos
Journal:  Int J Cancer       Date:  1993-07-30       Impact factor: 7.396

7.  Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma.

Authors:  A G Siccardi; G L Buraggi; L Callegaro; G Mariani; P G Natali; A Abbati; M Bestagno; V Caputo; L Mansi; R Masi
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

8.  HMFG-2 as a prognostic indicator in superficial bladder cancer.

Authors:  I G Conn; J Crocker; L A Emtage; D M Wallace
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

9.  Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase.

Authors:  H P Kalofonos; T R Pawlikowska; A Hemingway; N Courtenay-Luck; B Dhokia; D Snook; G B Sivolapenko; G R Hooker; C G McKenzie; P J Lavender
Journal:  J Nucl Med       Date:  1989-10       Impact factor: 10.057

10.  Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.

Authors:  M J Embleton; A Charleston; R A Robins; M V Pimm; R W Baldwin
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.